论文部分内容阅读
目的观察老年男性高血压并2型糖尿病患者服用安搏诺的有效性及安全性。方法观察56例老年男性高血压并2型糖尿病患者用药前、用药后1个月、用药后6个月的收缩压、舒张压、尿微量白蛋白、空腹血糖、糖化血红蛋白、血尿酸、尿素氮、血肌酐、总胆固醇、甘油三酯、高密度脂蛋白胆固醇、低密度脂蛋白胆固醇、血钾、血钠等生化指标并记录。为避免首次服药后血压迅速下降引起脏器低灌注,前3天口服安搏诺75 mg,1次/日,以血压达130～140/70～85 mmHg为标准,以后逐渐增加剂量,在血压递增过程中若血压低于100/60 mmHg,则返回至上次剂量,并以该剂量为此患者的以后剂量,连续服药半年。结果与服药前比较,患者服用安搏诺6个月时,收缩压、舒张压、尿微量白蛋白均较服药前明显降低,差异有统计学意义(P<0.01);空腹血糖、糖化血红蛋白、尿素氮、血肌酐虽然较服药前下降,但差异无统计学意义(P>0.05),总胆固醇、甘油三酯、高密度脂蛋白胆固醇、低密度脂蛋白胆固醇、血钾、血钠基本同服药前,差异无统计学意义(P>0.05)。56例患者中服药期间发生轻度头痛6例(10.7%),乏力8例(14.3%),但都不需减量或停药。结论老年男性高血压并2型糖尿病患者服用安搏诺(75～150 mg,1次/日),副作用少且多能耐受,是安全可行的。
Objective To observe the efficacy and safety of taking esuvinol in elderly male patients with type 2 diabetes and high blood pressure. Methods The systolic blood pressure, diastolic blood pressure, urine microalbuminuria, fasting blood glucose, glycosylated hemoglobin, blood uric acid, blood urea nitrogen, blood urea nitrogen, blood urea nitrogen and blood urea nitrogen in 56 elderly men with type 2 diabetes mellitus before treatment, 1 month after treatment and 6 months after treatment were observed. , Creatinine, total cholesterol, triglyceride, high density lipoprotein cholesterol, low density lipoprotein cholesterol, serum potassium, serum sodium and other biochemical indicators and record. In order to avoid the rapid decrease of blood pressure after the first medication, organoprost was administered orally 75 mg once daily for the first 3 days with the blood pressure of 130-140/70 to 85 mmHg as the standard. Afterwards, the dosage was gradually increased and blood pressure If the blood pressure is lower than 100/60 mmHg during the incrementing procedure, the dose is returned to the last dose, and for this patient the subsequent dose is taken for six months. Results Compared with those before medication, systolic blood pressure, diastolic blood pressure and urinary microalbumin were significantly lower than those before medication (P <0.01), fasting blood glucose, glycosylated hemoglobin, Blood urea nitrogen and serum creatinine were lower than those before medication, but the difference was not statistically significant (P> 0.05). Total cholesterol, triglyceride, high density lipoprotein cholesterol, low density lipoprotein cholesterol, serum potassium, Before the difference was not statistically significant (P> 0.05). Sixty-six patients (10.7%) had mild headache and 8 (14.3%) had mild fatigue during the medication period, but none of them required dose reduction or withdrawal. Conclusions It is safe and feasible to take fexemore (75-150 mg once a day) in elderly male patients with type 2 diabetes mellitus with less side effects and more tolerability.